Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aura Biosciences Prepares To Move Nano-Enabled Drug Delivery System Into The Clinic

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech's nanotechnology platform enables earlier detection of cancers and distant metastases, as well as targeted drug delivery.

You may also be interested in...



In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?

The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.

No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy

With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.

Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.

Topics

UsernamePublicRestriction

Register

PS072761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel